Some of small‐molecular NFκB inhibitors are approved and launched into clinical practice to treat various inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis and non‐specific inflammation.7 The gene discussed is NFKB1; the disease is inflammatory bowel disease.